

Haematologica
HAEMATOL/2018/207530
Version 3

Targeting sickle cell disease root-cause pathophysiology with small molecules

Yogen Saunthararajah

Disclosures: YS has equity, consultancy and board interest in EpiDestiny. YS has patents around decitabine, 5-azacytidine, tetrahydrouridine, ISWI (CHD4/SMARCA5) inhibition, and differentiation inducers to treat cancer.